Endocrine Abstracts

Experimental and epidemiological studies have implicated high serum GH and IGF1 levels as potential contributors to tumor progression by both endocrine and paracrine mechanisms. It is still a matter of debate, however, if the prevalence of cancer is increased in acromegaly, as this disorder, characterized by chronic GH and IGF1 hypersecretion, is also associated with elevated IGFBP3 levels, which has proapoptotic and anti-proliferative protective effects. On the other hand, no...

Pituitary carcinoma (PC) is defined by the presence of pituitary tumor that is either not contiguous with the primary sellar tumor and/or has metastasized to distant sites. It is very rare and associated with poor prognosis, with a median survival of 12 months when systemic metastases are present, and 30 months when metastases are confined to the central nervous system. A 20 years-old man was first diagnosed with a nonfunctioning pituitary macroadenoma in 1981 and submitted to...

Few studies have evaluated bone histomorphometry in type 2 diabetic patients (DM2) and none has established if the disease control plays a role on bone morphology and bone marrow adipocytes. The aim of this study is to present preliminary data on bone microstructure, bone formation rate and bone marrow adipocytes in premenopausal women with DM2 with different levels of glucose control. Bone biopsy, followed by tetracycline labelling, was obtained for analysis of static and dyn...

Objective: To investigate adherence to hormone replacement therapy (HRT) in patients with hypopituitarism in a tertiary center outpatient clinic.Patients and methods: Prospective, cross-sectional study of patients with hypopituitarism on HRT for at least two pituitary deficiencies (independent of diabetes insipidus). Medication adherence was assessed using a validated Portuguese version of four-item Morisky scale, in which participants were asked to indi...

Background: A systematic literature review (SLR) was conducted to assess the use of independent injections (self/partner/home-administered) as an alternative to healthcare-setting injections for chronic diseases. The primary objective was to identify studies reporting on independent injection of somatostatin analogues (SSAs). Comparative evidence on independent injection of other medications was examined as a secondary objective.Methods: MEDLINE/Embase/t...

Paltusotine is an investigational oral, once-daily, non-peptide, SST2 agonist in development for the treatment of acromegaly and neuroendocrine tumors. Interim analysis results from subjects with acromegaly treated with paltusotine for up to 2 years in ACROBAT Advance (NCT04261712), an ongoing, open-label extension study are reported here. Prior to Advance, subjects previously completed one of two Phase 2 parent studies, Evolve (NCT03792555, with normal IGF-1 using injected lo...

Background: Pasireotide is a multireceptor-targeted somatostatin analogue that predominantly binds to somatostatin receptor subtype 5 (SSTR5) and provides sustained control of urinary free cortisol (UFC) levels in some patients with Cushing’s disease (CD). Cabergoline is a dopamine D2 receptor agonist with efficacy in some patients with CD. Most corticotropinomas co-express SSTR5 and D2, providing rationale for combination treatment with pasireotide and cabergoline. Resul...

Paltusotine is a once-daily, oral selective nonpeptide somatostatin receptor type 2 (SST2) agonist, which is in clinical development for the treatment of acromegaly. Maintenance of insulin-like growth factor 1 (IGF-1) control and toleration was demonstrated in phase 2 studies evaluating paltusotine in biochemically controlled (IGF-1 ≤1xULN) [ACROBAT Evolve (NCT03792555)] and uncontrolled (1> IGF-1 ≤2.5xULN) [ACROBAT Edge (NCT03789656)] patients with acromegaly ...

Paltusotine is a once-daily, oral, nonpeptide somatostatin receptor type 2 (SST2) specific agonist, in development for the treatment of acromegaly and neuroendocrine tumors. We report interim results from ACROBAT Advance (NCT04261712), an ongoing, multicenter, open-label, long-term extension study of paltusotine in subjects with acromegaly who previously completed either Phase 2 study ACROBAT Edge (NCT03789656) or Evolve (NCT03792555). ACROBAT Edge enrolled 47 subjects with el...

Pituitary adenomas and phaeochromocytoma/paragangliomas (PHAEO/PGL) can very rarely occur in the same patient or in the same family. Together, they are not known to be part of any classical endocrine neoplasia syndromes. In some caes the pathogenetic mechanism may be secondary to a PHAEO secreting GHRH leading to somatotroph hyperplasia and clinical acromegaly. However, we suggest several other mechanisms which could lead to the development of pituitary and PHAEO/PGL together:...